FGen is an emerging Swiss biotech company active as a contract research organization in strain development and optimization. Key technologies are methods for biological engineering, such as Synthetic Biology or non-GMO methods, and a proprietary screening platform for high throughput screening. In 2022 was acquired by Ginkgo Bioworks.